Original Article

Hypertension Research (2008) 31, 161–168; doi:10.1291/hypres.31.161

Attenuation of Focal Brain Ischemia by Telmisartan, an Angiotensin II Type 1 Receptor Blocker, in Atherosclerotic Apolipoprotein E-Deficient Mice

Masaru Iwai, Shinji Inaba, Yumiko Tomono, Harumi Kanno, Jun Iwanami, Masaki Mogi and Masatsugu Horiuchi

Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Japan

Correspondence: Masatsugu Horiuchi, M.D., Ph.D., Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon 791-0295, Japan. E-mail: horiuchi@m.ehime-u.ac.jp

Received 1 June 2007; Accepted 5 August 2007.

Top

Abstract

The effects of an angiotensin II (Ang II) type 1 (AT1) receptor blocker (ARB) on focal brain ischemia and atherosclerotic lesions were explored in atherosclerotic apolipoprotein E-deficient (ApoEKO) mice treated with a high-cholesterol diet (HCD). The ischemic brain area and neurological deficit 24 h after middle cerebral artery (MCA) occlusion were significantly greater in ApoEKO mice treated with HCD for 10 weeks than in those with a normal standard diet. The reduction of cerebral surface blood flow in the penumbral region and the increase in superoxide production in the ischemic area were exaggerated in HCD-treated ApoEKO mice. Histological analysis showed atherosclerotic changes in the proximal aorta and deposition of lipid droplets in the arterial wall in the brain. Administration of an ARB, telmisartan (0.3 mg/kg/day), for the last 2 weeks after 8 weeks of HCD feeding attenuated the ischemic brain area, the neurological deficit, the superoxide production in the ischemic area, and the reduction of cerebral blood flow in the penumbra, without significantly changing blood pressure or serum cholesterol level. Telmisartan also decreased atherosclerotic lesion formation in the proximal aorta of HCD-treated ApoEKO mice, although it did not remarkably change lipid deposition in the cerebral arteries. These results suggest that the blockade of the AT1 receptor attenuates ischemic brain damage induced in an atherosclerosis model. This inhibitory action is mediated through the attenuation of the reduction in cerebral blood flow and of oxidative stress in the brain; it also mediated through telmisartan's anti-atherosclerotic effect. (Hypertens Res 2008; 31: 161-168)

Keywords:

cerebral ischemia, atherosclerosis, angiotensin, receptors, oxidative stress

Top

References

  1. Spagnoli LG, Mauriello A, Sangiorgi G, et al: Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004; 292: 1845–1852. | Article | PubMed | ChemPort |
  2. Nissen SE, Tuzcu EM, Libby P, et al, CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225. | Article | PubMed | ISI | ChemPort |
  3. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al: Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657–663. | Article | PubMed | ISI |
  4. Walther T, Olah L, Harms C, et al: Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16: 169–176. | Article | PubMed | ChemPort |
  5. Iwai M, Liu H-W, Chen R, et al: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843–848. | Article | PubMed | ChemPort |
  6. Saavedra JM, Benicky J, Zhou J: Mechanisms of the anti-ischemic effect of angiotensin II AT1 receptor antagonists in the brain. Cell Mol Neurobiol 2006; 26: 1099–1111. | PubMed | ChemPort |
  7. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM: Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297–2303. | Article | PubMed | ChemPort |
  8. Tsuda M, Iwai M, Li JM, et al: Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545–551. | Article | PubMed | ChemPort |
  9. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G: Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062–3067. | Article | PubMed | ChemPort |
  10. Iwai M, Chen R, Li Z, et al: Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005; 112: 1636–1643. | Article | PubMed | ChemPort |
  11. Hata R, Mies G, Wiessner C, et al: A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 1998; 18: 367–375. | Article | PubMed | ISI | ChemPort |
  12. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883–1885. | Article | PubMed | ISI | ChemPort |
  13. Connolly ES Jr, Winfree CJ, Springer TA, et al: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209–216. | Article | PubMed | ISI | ChemPort |
  14. Tabrizi P, Wang L, Seeds N, et al: Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol 1999; 19: 2801–2806. | PubMed | ISI | ChemPort |
  15. Szocs K, Lassegue B, Sorescu D, et al: Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22: 21–27. | Article | PubMed | ISI | ChemPort |
  16. Biswas SK, Newby DE, Rahman I, Megson IL: Depressed glutathione synthesis precedes oxidative stress and atherogenesis in Apo-E(-/-) mice. Biochem Biophys Res Commun 2005; 338: 1368–1373. | Article | PubMed | ChemPort |
  17. Guzik TJ, Sadowski J, Guzik B, et al: Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 333–339. | Article | PubMed | ChemPort |
  18. Yoshii T, Iwai M, Li Z, et al: Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29: 457–466. | Article | PubMed | ChemPort |
  19. Dahlof B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003. | Article | PubMed | ISI | ChemPort |
  20. Lithell H, Hansson L, Skoog I, et al, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886. | Article | PubMed | ISI | ChemPort |
  21. Schiffrin EL: Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study. Curr Hypertens Rep 2002; 4: 39–40. | Article | PubMed |
  22. Jöhren O, Imboden H, Häuser W, Maye I, Sanvitto GL, Saavedra JM: Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997; 757: 218–227. | Article | PubMed | ISI | ChemPort |
  23. Tamura K, Yokoyama N, Sumida Y, et al: Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knockout mice. J Endocrinol 1999; 160: 401–408. | Article | PubMed | ChemPort |
  24. Davisson RL, Yang G, Beltz TG, Cassell MD, Johnson AK, Sigmund CD: The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res 1998; 83: 1047–1058. | PubMed | ChemPort |
  25. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD: Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 2000; 106: 103–106. | Article | PubMed | ChemPort |
  26. Li Z, Iwai M, Wu L, et al: Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 2003; 284: H116–H121. | PubMed | ChemPort |
  27. Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253–2261. | Article | PubMed | ISI | ChemPort |
  28. Vitale C, Mercuro G, Castiglioni C, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6. | Article | PubMed | ChemPort |
  29. Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442–3452. | Article | PubMed | ChemPort |
  30. Derosa G, Cicero AFG, D'Angelo A, et al: Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849–856. | Article | PubMed | ChemPort |
  31. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993–1002. | Article | PubMed | ISI | ChemPort |
  32. Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 2005; 42 (Suppl 1): S9–S16. | Article | PubMed | ISI | ChemPort |
  33. Luo Y, Yin W, Signore AP, et al: Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435–448. | Article | PubMed | ISI | ChemPort |

Extra navigation

.

naturejobs

More science jobs
Post a job for free
ADVERTISEMENT